Skip to main content
. 2022 Mar 3;6(5):1490–1498. doi: 10.1182/bloodadvances.2021005357

Figure 2.

Figure 2.

PFS and OS. (A) PFS for all participants. (B) PFS for the optimal dose, arm B (IBR 420 mg daily and VEN 200 mg daily). (C) OS for all participants. (D) OS for the optimal dose, arm B (IBR 420 mg daily and VEN 200 mg daily).